The rebound of lipoproteins after LDL-apheresis. Effects on chemical composition and LDL-oxidizability

Atherosclerosis

Volumn 147, Issue 1, 1999, Pages 105-113

  Kroon, Abraham A ^a   Demacker, Pierre N M ^a   Kleinveld, Henne A ^a   Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Atherosclerosis; Conjugated dienes; LDL apheresis; Lipid lowering; Oxidative modification; Vitamin E

Indexed keywords

ALKADIENE; ALPHA TOCOPHEROL; APOLIPOPROTEIN B; ARACHIDONIC ACID; CHOLESTEROL; DEXTRAN SULFATE; FATTY ACID; LINOLEIC ACID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PALMITIC ACID; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; APHERESIS; ARTICLE; CHEMICAL COMPOSITION; CLINICAL ARTICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; MALE; NEPHELOMETRY; OXIDATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; BLOOD COMPONENT REMOVAL; CHOLESTEROL; CHOLESTEROL ESTERS; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; FATTY ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; SIMVASTATIN; VITAMIN E;

EID: 0032853935     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00177-X     Document Type: Article

References (45)

1. Superko H.R., Krauss R.M. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation. 90:1994;1056-1069.
2. Mabuchi H., Michishita I., Takeda M., Fujita H. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis. 68:1987;19-25.
3. Gordon B.R., Daal S.D. Advances in LDL-apheresis for the treatment of severe hypercholesterolemia. Curr Opin Lipidol. 5:1994;69-73.
4. Thompson G.R., Maher W.M.G., Matthews S. et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 345:1995;811-816.
5. Kroon A.A., Aengevaeren W.R.M., van der Werf T. et al. The LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 93:1996;1826-1835.
6. Apstein C.S., Zilversmith D.B., Lees R.S., George P.K. Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis. 31:1978;105-115.
7. Kroon A.A., van't Hof M.A., Stalenhoef A.F.H. Assessment of time-averaged levels in treatment of hypercholesterolemia by LDL-apheresis (LA). Neth J Med. 40:1992;A50-A51.
8. Pfohl M., Naoumova R.P., Klass C. et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res. 35:1994;1946-1955.
9. Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 76:1979;333-337.
10. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol: modification of low density lipoprotein that increases its atherogenicity. N Engl J Med. 320:1989;915-924.
11. Aviram M., Rosenblat M. Macrophage-mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor. J Lipid Res. 35:1994;385-398.
12. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witztum J.L., Steinberg D. Modification of low density lipoproteins by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA. 81:1984;3883-3887.
13. Rosenfeld M.E., Khoo J.C., Miller E., Parthasarathy S., Palinski W., Witztum J.L. Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low-density lipoproteins, and contain oxidation specific lipid-protein adducts. J Clin Invest. 87:1991;90-99.
14. Kita T., Nagano Y., Yokode M. et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA. 84:1987;5928-5931.
15. Williams R.J., Motteram J.M., Sharp C.H., Gallagher P.J. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis. 94:1992;153-159.
16. Fruebis J., Steinberg D., Dresel H.A., Carew T.E. A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest. 94:1994;392-398.
17. Kleinveld H.A., Hak-Lemmers H.L.M., Hectors M.P.C., de Fouw N.J., Demacker P.N.M., Stalenhoef A.F.H. Vitamin E and fatty acid intervention does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 15:1995;290-297.
18. Esterbauer H., Dieber-Rotheneder M., Waeg G., Striegl G., Juergens G. Biochemical, structural, and functional properties of oxidized low-density lipoprotein. Chem Res Toxicol. 3:1990;77-92.
19. de Graaf J., Hak-Lemmers H.L.M., Hectors M.P.C., Demacker P.N.M., Hendriks J.C.M., Stalenhoef A.F.H. Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 11:1991;298-306.
20. Kleinveld H.A., Hak-Lemmers H.L.M., Stalenhoef A.F.H., Demacker P.N.M. Improved measurement of low-density lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein. Clin Chem. 38:1992;2066-2072.
21. Kleinveld H.A., Naber A.H.J., Stalenhoef A.F.H., Demacker P.N.M. Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio oleic acid content to linoleic acid content: studies in vitamin E deficient subject. Free Radic Biol Med. 15:1993;273-280.
22. Cominacini L., Garbin U., Pastorino A.M. et al. Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Atherosclerosis. 99:1993;63-70.
23. Aviram M., Lund-Katz S., Philips M.C., Chait A. The influence of the triglyceride content of low density lipoprotein on the interaction of apolipoprotein B-100 with cells. J Biol Chem. 263:1988;16842-16848.
24. Jadhav A.V., Thompson G.R. Reversible abnormalities of low density lipoprotein composition in familial hypercholesterolaemia. Eur J Clin Invest. 9:1979;63-67.
25. Franceschini G., Apebe P., Calabresi L. et al. Alterations in the HDL system after rapid plasma cholesterol reduction by LDL-apheresis. Metabolism. 37:1988;752-757.
26. Gandjini H., Gambert P., Athias A., Mousson C., Rifle G., Lallemant C. Composition and immunoreactivity of serum low density lipoproteins (LDL) before and after LDL-apheresis on dextran sulphate-cellulose columns. Transf Sci. 15:1994;289-297.
27. Leitinger N., Pirich C., Blazek I., Endler G., Sinzinger H. Decreased susceptibility of low density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment. Atherosclerosis. 126:1996;303-312.
28. Napoli C., Ambrosio G., Scarpato N. et al. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J. 133:1997;585-595.
29. Kroon A.A., van Asten W.N.J.C., Stalenhoef A.F.H. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med. 125:1996;945-954.
30. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 34:1955;1345-1353.
31. Lowry O.H., Rosebrough N.J., Farr L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275.
32. Demacker P.N.M., Hijmans A.G., Vos-Jansen H.E., van't Laar A., Jansen A.P. A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin Chem. 26:1980;1775-1779.
33. Lopes-Virella M.F., Virella G., Evans G., Malenkos S.B., Colwell J.A. Immunonephelometric assay of human apolipoprotein AI. Clin Chem. 26:1980;1205-1208.
34. Kleinveld H.A., Demacker P.N.M., de Haan A.F.J., Stalenhoef A.F.H. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest. 23:1993;289-295.
35. Bredie S.J.H., de Bruin T.W.A., Demacker P.N.M., Kastelein J.J.P., Stalenhoef A.F.H. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol. 75:1995;348-353.
36. Esterbauer H., Jurgens G. Mechanistic and genetic aspects of susceptibility of LDL to oxidation. Curr Opin Lipidol. 4:1993;114-124.
37. Princen H.M., van Duyvenvoorde W., Buytenhek R. et al. Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and women. Arterioscler Thromb. 15:1995;325-333.
38. Bräutigam C., Engelmann B., Reiss D. et al. Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis. Atherosclerosis. 119:1996;77-88.
39. Swinkels D.W., Hak-Lemmers H.L.M., Demacker P.N.M. Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low density lipoprotein subfractions. J Lipid Res. 28:1987;1233-1239.
40. Chahboun S., Tallineau C., Pontcharraud R., Guettier A., Piriou A. Polyunsaturated fatty acid profiles and α-tocopherol levels in plasma and whole blood incubated with copper: evidence of inhibition of lipoperoxidation in plasma by hemolysate. Biochim Biophys Acta. 1042:1990;32432-32439.
41. Krauss R.M. Heterogeneity of plasma low-density lipoproteins and atherosclerotic risk. Curr Opin Lipidol. 5:1994;339-349.
42. Chapman M.J., Laplaud P.M., Luc G. et al. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res. 29:1988;442-458.
43. Checovich W.J., Aiello R.J., Attie A.D. Overproduction of buoyant low density lipoprotein subspecies in spontaneously hypercholesterolemic mutant pigs. Arteriosclerosis. 11:1991;351-361.
44. Stalenhoef A.F.H., Defesche J.C., Kleinveld H.E., Demacker P.N.M., Kastelein J.J.P. Decreased resistance against in vitro oxidation of LDL from patients with familial defective apolipoprotein B-100. Arterioscler Thromb. 14:1994;489-493.
45. de Graaf J., Hendriks J.C.M., Demacker P.N.M., Stalenhoef A.F.H. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects: normalization after clofibrate treatment. Arterioscler Thromb. 13:1993;712-719.